Report – UDI-related Issues in Form 483s: Where Should You Focus Mitigation Efforts?

Report – Analysis of FDA Drug GMP Warning Letters for FYs 2020 and 2021

Report – GMP Issues With COVID Vaccines and Drugs are Not New Concerns

Webinar – UDI | Aligning to a Single Approach

Redica Systems Announces $30M Series B

Redica Systems Announces $30M Series B Led by Savant Growth to Bring New Analytics and Compliance Platform to FDA-Regulated Life Sciences Companies Investment To Help Extend Lead in Quality and Regulatory Intelligence for FDA-regulated Industries PLEASANTON, CA, December 9, 2021 — Redica Systems, a cloud-based data intelligence platform serving FDA-regulated industries, announced it has secured […]

Report – The Current Pharmaceutical Quality Landscape

Webinar – Past, Present, and Future of Quality Culture

Panel Discussion – Changing Medical Device Regulations

Report – An In-Depth Look at Combination Product Regulations

New York Times | Sept. 19, 2021

  In this op/ed column, the author describes findings from a pharmaceutical plant inspection using information from Redica Systems. Click here to access the article (article is behind a paywall).
« Older Entries
Newer Entries »